|
1
|
Pinar T, Akdur R, Tuncbilek A, Altundag K
and Cengiz M: The relationship between occupations and head and
neck cancers. J Natl Med Assoc. 99:64, 68–71. 2007.
|
|
2
|
Harréus U: Surgical errors and risks - the
head and neck cancer patient. GMS Curr Top Otorhinolaryngol Head
Neck Surg. 12:Doc042013.PubMed/NCBI
|
|
3
|
Kaplan EL: Postoperative irradiation with
or without concomitant chemotherapy for locally advanced head and
neck cancer. N Engl J Med. 9:133–134. 2005.
|
|
4
|
Miah AB, Schick U, Bhide SA,
Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L,
Thway K, Wilson P, et al: A phase II trial of induction
chemotherapy and chemo-IMRT for head and neck squamous cell cancers
at risk of bilateral nodal spread: The application of a bilateral
superficial lobe parotid-sparing IMRT technique and treatment
outcomes. Br J Cancer. 112:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nutting C, Harrington K, Rogers MS,
Sydenham MA, A'Hern R and Hall M: Results of a phase III
multi-centre randomised controlled trial of intensity modulated
(IMRT) vs. conventional radiotherapy (RT) in head and neck cancer
(PARSPORT: ISRCTN48243537; CRUK/03/005). Clin Oncol. 22:8992009.
View Article : Google Scholar
|
|
6
|
Monroe AT, Young JA, Ernster JA, Huff JD
and Peddada AV: Acute toxicity of concomitant boost IMRT and
chemotherapy for gead and neck cancer in the community setting. Int
J Radiat Oncol Biol Phys. 72:S4132008. View Article : Google Scholar
|
|
7
|
Nutting CM, Morden JP, Harrington KJ,
Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay
M, et al PARSPORT trial management group, : Parotid-sparing
intensity modulated versus conventional radiotherapy in head and
neck cancer (PARSPORT): A phase 3 multicentre randomised controlled
trial. Lancet Oncol. 12:127–136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kreppel M, Eich HT, Kübler A, Zöller JE
and Scheer M: Prognostic value of the sixth edition of the UICC's
TNM classification and stage grouping for oral cancer. J Surg
Oncol. 102:443–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yanagawa M, Tatsumi M, Miyata H, Morii E,
Tomiyama N, Watabe T, Isohashi K, Kato H, Shimosegawa E, Yamasaki
M, et al: Evaluation of response to neoadjuvant chemotherapy for
esophageal cancer: PET response criteria in solid tumors versus
response evaluation criteria in solid tumors. J Nucl Med.
53:872–880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen AP, Setser A, Anadkat MJ, Cotliar J,
Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse
events of cancer treatments: The Common Terminology Criteria for
Adverse Events version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clavel S, Nguyen DH, Fortin B, Després P,
Khaouam N, Donath D, Soulières D, Guertin L and Nguyen-Tan PF:
Simultaneous integrated boost using intensity-modulated
radiotherapy compared with conventional radiotherapy in patients
treated with concurrent carboplatin and 5-fluorouracil for locally
advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys.
82:582–589. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parliament M, Alidrisi M, Munroe M,
Wolfaardt J, Scrimger R, Thompson H, Field C, Kurien E and Hanson
J: Implications of radiation dosimetry of the mandible in patients
with carcinomas of the oral cavity and nasopharynx treated with
intensity modulated radiation therapy. Int J Oral Maxillofac Surg.
34:114–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao M, Dornfeld KJ, Buatti JM, Skwarchuk
M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, et al:
Intensity-modulated radiation treatment for head-and-neck squamous
cell carcinoma - the University of Iowa experience. Int J Radiat
Oncol Biol Phys. 63:410–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang K, Xia P, Chuang C, Weinberg V,
Glastonbury CM, Eisele DW, Lee NY, Yom SS, Phillips TL and Quivey
JM: Intensity-modulated chemoradiation for treatment of stage III
and IV oropharyngeal carcinoma: The University of California-San
Francisco experience. Cancer. 113:497–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Daly ME, Le QT, Maxim PG, Loo BW Jr,
Kaplan MJ, Fischbein NJ, Pinto H and Chang DT: Intensity-modulated
radiotherapy in the treatment of oropharyngeal cancer: Clinical
outcomes and patterns of failure. Int J Radiat Oncol Biol Phys.
76:1339–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Monnerat C, Faivre S, Temam S, Bourhis J
and Raymond E: End points for new agents in induction chemotherapy
for locally advanced head and neck cancers. Ann Oncol. 13:995–1006.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al EORTC 24971/TAX 323 Study Group, : Cisplatin,
fluorouracil, and docetaxel in unresectable head and neck cancer. N
Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rosenthal DI, Harris J, Forastiere AA,
Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K,
Schultz CJ, et al: Early postoperative paclitaxel followed by
concurrent paclitaxel and cisplatin with radiation therapy for
patients with resected high-risk head and neck squamous cell
carcinoma: Report of the phase II trial RTOG 0024. J Clin Oncol.
27:4727–4732. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balukrishna S, Pilaka VKR, Michael RC,
Samuel P and Ravindran PB: Hyper-fractionated intensity modulated
radiation therapy (HF-IMRT) in head and neck cancer: The technical
feasibility and results of a short clinical series. J Clin Diagn
Res. 9:XR01–XR04. 2015.PubMed/NCBI
|
|
20
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors. J Nucl Med. 50 Suppl 1:122S–150S. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoeller U, Tribius S, Kuhlmey A, Grader K,
Fehlauer F and Alberti W: Increasing the rate of late toxicity by
changing the score? A comparison of RTOG/EORTC and LENT/SOMA
scores. Int J Radiat Oncol Biol Phys. 55:1013–1018. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelly JR, Husain ZA and Burtness B:
Treatment de-intensification strategies for head and neck cancer.
Eur J Cancer. 68:125–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
